Squamous cell carcinoma - Pladecellecarcinomhttps://en.wikipedia.org/wiki/Squamous_cell_carcinoma
Pladecellecarcinom (Squamous cell carcinoma) er almindeligvis en rød, skælvende, fortykket læsion på soleksponeret hud. Nogle er faste hårde knuder og kuppelformet som keratoacanthomas. Sårdannelse og blødning kan forekomme. Når pladecellecarcinom (squamous cell carcinoma) ikke behandles, kan det udvikle sig til en stor masse. Planocellulært celle er den næsthyppigste hudkræft. Det er farligt, men ikke nær så farligt som et melanom. Efter biopsien vil den blive fjernet kirurgisk.

Diagnose og behandling
#Dermoscopy
#Skin biopsy
☆ I 2022 Stiftung Warentest-resultaterne fra Tyskland var forbrugernes tilfredshed med ModelDerm kun lidt lavere end med betalte telemedicinske konsultationer.
  • Squamous cell carcinoma well differentiated ― En tilstødende aktinisk keratose observeres.
  • Keratoacanthoma
  • Keratoacanthoma
  • Pladecellecarcinom (Squamous cell carcinoma) ― Underarm
  • Hvis et sår ikke heler i lang tid, skal der være mistanke om hudkræft.
  • Hvis et sår ikke heler i lang tid, skal der være mistanke om hudkræft.
References Squamous Cell Skin Cancer 28722968 
NIH
Squamous cell carcinoma (SCC) er den næsthyppigste hudkræft i USA, efter basal cell carcinoma. Det starter normalt fra præcancerøse læsioner kaldet actinic keratosis og kan spredes til andre dele af kroppen. Hovedårsagen er eksponering for ultraviolet (UV) stråling fra solen, som akkumuleres over tid. Behandling involverer normalt kirurgisk fjernelse, især for SCC på hoved og hals. Strålebehandling er en mulighed for ældre patienter eller dem, der ikke kan opereres. Immunsuppression øger risikoen for SCC. Selvom det er sjældent, kan SCC spredes, især hos patienter med svækket immunsystem. Regelmæssig kontrol og solbeskyttelse er vigtigt for dem med SCC.
Squamous cell carcinoma of the skin or cutaneous squamous cell carcinoma is the second most common form of skin cancer in the United States, behind basal cell carcinoma. Squamous cell carcinoma has precursor lesions called actinic keratosis, exhibits tumor progression and has the potential to metastasize in the body. Ultraviolet (UV) solar radiation is the primary risk factor in the development of cutaneous squamous cell carcinoma and the cumulative exposure received over a lifetime plays a major part in the development of this cancer. Surgical excision is the primary treatment modality for cutaneous squamous cell carcinoma, with Mohs micrographic surgery being the preferred excisional technique for squamous cell carcinoma of the head and neck, and in other areas of high risk or squamous cell carcinoma with high-risk characteristics. Radiation therapy is reserved for squamous cell carcinoma in older patients or those who will not tolerate surgery, or when it has not been possible to obtain clear margins surgically. Adjuvant radiotherapy is commonly after surgical treatment in very high tumors. Immunosuppression significantly increases the risk of squamous cell carcinoma over the course of an individual’s life. Metastasis is uncommon for squamous cell carcinomas arising in areas of chronic sun exposure, but it can take place, and the risk is increased in immunosuppressed patients. Patients with cutaneous squamous cell carcinoma should be examined regularly and remember to use measures to protect from UV damage.
 Cutaneous Squamous Cell Carcinoma: From Biology to Therapy 32331425 
NIH
Cutaneous squamous cell carcinoma (CSCC) er den næsthyppigste kræftsygdom hos mennesker, og antallet er stigende. Selvom CSCC normalt udviser en godartet klinisk adfærd, kan den spredes både lokalt og til andre dele af kroppen. Forskere har identificeret specifikke veje involveret i CSCC-udvikling, hvilket fører til nye behandlinger. Det høje antal mutationer og øget risiko hos immunsupprimerede patienter har foranlediget udviklingen af ​​immunterapi. Denne anmeldelse ser på de genetiske rødder af CSCC og de seneste behandlinger rettet mod specifikke molekyler og immunsystemet.
Cutaneous squamous cell carcinoma (CSCC) is the second most frequent cancer in humans and its incidence continues to rise. Although CSCC usually display a benign clinical behavior, it can be both locally invasive and metastatic. The signaling pathways involved in CSCC development have given rise to targetable molecules in recent decades. In addition, the high mutational burden and increased risk of CSCC in patients under immunosuppression were part of the rationale for developing the immunotherapy for CSCC that has changed the therapeutic landscape. This review focuses on the molecular basis of CSCC and the current biology-based approaches of targeted therapies and immune checkpoint inhibitors